The role of the mediators of inflammation in cancer development
- PMID: 25740073
- DOI: 10.1007/s12253-015-9913-z
The role of the mediators of inflammation in cancer development
Abstract
Epigenetic disorders such as point mutations in cellular tumor suppressor genes, DNA methylation and post-translational modifications are needed to transformation of normal cells into cancer cells. These events result in alterations in critical pathways responsible for maintaining the normal cellular homeostasis, triggering to an inflammatory response which can lead the development of cancer. The inflammatory response is a universal defense mechanism activated in response to an injury tissue, of any nature, that involves both innate and adaptive immune responses, through the collective action of a variety of soluble mediators. Many inflammatory signaling pathways are activated in several types of cancer, linking chronic inflammation to tumorigenesis process. Thus, Inflammatory responses play decisive roles at different stages of tumor development, including initiation, promotion, growth, invasion, and metastasis, affecting also the immune surveillance. Immune cells that infiltrate tumors engage in an extensive and dynamic crosstalk with cancer cells, and some of the molecular events that mediate this dialog have been revealed. A range of inflammation mediators, including cytokines, chemokines, free radicals, prostaglandins, growth and transcription factors, microRNAs, and enzymes as, cyclooxygenase and matrix metalloproteinase, collectively acts to create a favorable microenvironment for the development of tumors. In this review are presented the main mediators of the inflammatory response and discussed the likely mechanisms through which, they interact with each other to create a condition favorable to development of cancer.
Similar articles
-
Inflammation and cancer: an ancient link with novel potentials.Int J Cancer. 2007 Dec 1;121(11):2373-80. doi: 10.1002/ijc.23173. Int J Cancer. 2007. PMID: 17893866 Review.
-
Inflammation: gearing the journey to cancer.Mutat Res. 2008 Jul-Aug;659(1-2):15-30. doi: 10.1016/j.mrrev.2008.03.002. Epub 2008 Mar 16. Mutat Res. 2008. PMID: 18485806 Review.
-
From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation.J Pathol. 2013 Jan;229(2):198-207. doi: 10.1002/path.4103. Epub 2012 Nov 20. J Pathol. 2013. PMID: 22996812 Review.
-
Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation.Gastroenterology. 2012 Sep;143(3):550-563. doi: 10.1053/j.gastro.2012.07.009. Epub 2012 Jul 13. Gastroenterology. 2012. PMID: 22796521 Review.
-
The fundamental role of mechanical properties in the progression of cancer disease and inflammation.Rep Prog Phys. 2014 Jul;77(7):076602. doi: 10.1088/0034-4885/77/7/076602. Epub 2014 Jul 9. Rep Prog Phys. 2014. PMID: 25006689 Review.
Cited by
-
BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway.Cell Mol Immunol. 2017 Oct;14(10):830-841. doi: 10.1038/cmi.2016.31. Epub 2016 Jul 4. Cell Mol Immunol. 2017. PMID: 27374794 Free PMC article.
-
Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs.Biosci Rep. 2018 Nov 13;38(6):BSR20181253. doi: 10.1042/BSR20181253. Print 2018 Dec 21. Biosci Rep. 2018. PMID: 30287506 Free PMC article. Review.
-
Association Between Metabolic Syndrome and Breast Cancer Risk: An Updated Meta-Analysis of Follow-Up Studies.Front Oncol. 2019 Nov 22;9:1290. doi: 10.3389/fonc.2019.01290. eCollection 2019. Front Oncol. 2019. PMID: 31824862 Free PMC article.
-
DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway.Inflammation. 2019 Apr;42(2):672-681. doi: 10.1007/s10753-018-0924-2. Inflammation. 2019. PMID: 30506106
-
Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.Oncologist. 2017 Jun;22(6):737-742. doi: 10.1634/theoncologist.2016-0443. Epub 2017 May 22. Oncologist. 2017. PMID: 28533476 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources